Allergy Therapeutics plc
("Allergy Therapeutics", the "Group" or "Company")
Allergy Therapeutics announces that Nick Wykeman is to step down as Chief Financial Officer
26 May 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that Nick Wykeman, Chief Financial Officer and Board Director, aged 57, has tendered his resignation, with effect from 30 November 2022, in order to pursue non-executive roles.
Nick Wykeman, who has been a Director of Allergy Therapeutics for six years, remains in his role for six months and a search for his successor will now commence.
Manuel Llobet, Chief Executive Officer, commented: "We are very sorry that Nick Wykeman has decided to leave the Company after a successful period with the business but fully understand his decision. I should like to take this opportunity to thank him for his dedication and insight over the past six years and look forward to his replacement joining the Group."
Nick Wykeman, Chief Financial Officer, added: "It has been a privilege to serve as Allergy Therapeutics' Chief Financial Officer over the past six years and I wish the Company and its employees continued success in the future. I will remain focused on the role over the coming months and ensure an orderly handover to my successor."
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon (Nominated Adviser and Broker)
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
